David Craig, a biotechnology founder and industry operator, has released 'The New Rules of Biotech: A Founder’s Guide to Building Great Companies' in hardcover ($29.99) and audiobook on Google Play, joining the existing paperback ($21.99) and Kindle ($11.99) editions on Amazon. The book addresses the fundamental shift in the biotech landscape since 2021, where capital is more expensive, FDA standards have evolved, and the Inflation Reduction Act has altered drug economics before approval.
Drawing from his experience founding Sarcomatrix Therapeutics, Craig provides a practical manual for building companies under current conditions. Topics include choosing between platform and asset strategies, selecting affordable modalities, raising seed rounds based on milestones, and using non-dilutive capital strategically. The book covers IND-enabling work, CMC, clinical decisions, term sheets, board dynamics, business development, and exits such as acquisitions and IPOs.
Craig emphasizes that the book is for founders, investors, board members, and operators, with each chapter offering takeaways tailored to both sides of the table. The audiobook format allows listeners to engage with the material on the go. Craig’s motivation stems from a personal connection to RYR-1 related congenital muscular dystrophy, underscoring the responsibility beyond financial returns in biotech.
Available formats include hardcover at Amazon, paperback at Amazon, Kindle at Amazon, and audiobook at Google Play. The book is published by D. Craig Consulting LLC and categorized under Business and Money, Business Development and Entrepreneurship.
